X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (513) 513
humans (425) 425
index medicus (420) 420
male (374) 374
quinoxalines - pharmacology (349) 349
quinoxalines - pharmacokinetics (284) 284
pharmacology & pharmacy (254) 254
rats (247) 247
female (231) 231
quinoxalines - administration & dosage (171) 171
mice (168) 168
quinoxalines - therapeutic use (150) 150
varenicline (130) 130
quinoxalines - chemistry (127) 127
neurosciences (122) 122
adult (112) 112
dose-response relationship, drug (112) 112
quinoxalines - adverse effects (108) 108
middle aged (102) 102
chemistry, medicinal (98) 98
quinoxalines - metabolism (92) 92
rats, sprague-dawley (88) 88
pharmacokinetics (86) 86
analysis (79) 79
brimonidine tartrate (76) 76
quinoxalines - chemical synthesis (74) 74
aged (69) 69
structure-activity relationship (68) 68
oncology (67) 67
excitatory amino acid antagonists - pharmacology (65) 65
receptor partial agonist (65) 65
rats, wistar (64) 64
smoking cessation - methods (63) 63
in-vitro (60) 60
treatment outcome (60) 60
smoking cessation (59) 59
tissue distribution (59) 59
benzazepines - therapeutic use (58) 58
in vitro techniques (56) 56
molecular structure (54) 54
drugs (53) 53
quinoxaline (53) 53
toxicology (53) 53
pharmacology/toxicology (52) 52
research (52) 52
sustained-release bupropion (50) 50
nicotine (49) 49
efficacy (48) 48
enzyme inhibitors - pharmacology (48) 48
benzazepines - adverse effects (47) 47
chemistry, organic (47) 47
quinoxalines - blood (47) 47
chromatography, high pressure liquid (46) 46
pharmacology (45) 45
smoking-cessation (45) 45
article (44) 44
biochemistry & molecular biology (44) 44
cancer (44) 44
imidazoles - pharmacokinetics (44) 44
metabolites (44) 44
care and treatment (43) 43
drug therapy (43) 43
administration, oral (42) 42
benzazepines - administration & dosage (42) 42
quinoxalines (42) 42
biotransformation (41) 41
cells, cultured (39) 39
double-blind method (39) 39
smoking cessation programs (39) 39
quinoxalines - toxicity (38) 38
medicine & public health (37) 37
psychiatry (37) 37
benzazepines - pharmacology (36) 36
glutamate (36) 36
health aspects (36) 36
rabbits (36) 36
adolescent (35) 35
antineoplastic agents - pharmacology (35) 35
oxadiazoles - pharmacology (35) 35
safety (35) 35
benzazepines - pharmacokinetics (34) 34
derivatives (34) 34
mice, inbred c57bl (34) 34
receptors, ampa - antagonists & inhibitors (34) 34
smoking (34) 34
biomedicine (33) 33
brimonidine (33) 33
cell line, tumor (33) 33
nicotinic agonists - therapeutic use (33) 33
rat (33) 33
time factors (33) 33
disease models, animal (32) 32
expression (32) 32
liver - metabolism (32) 32
metabolism (32) 32
nicotinic agonists - adverse effects (32) 32
apoptosis (31) 31
chemistry, analytical (31) 31
drug interactions (31) 31
mutagens - pharmacokinetics (31) 31
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (842) 842
German (6) 6
Russian (2) 2
French (1) 1
Japanese (1) 1
Norwegian (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2017, Volume 57, Issue 12, pp. 1616 - 1624
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 5/2019, Volume 75, Issue 5, pp. 665 - 675
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3520 - 3528
Purpose: This phase Ib study was designed to determine the MTD, safety, preliminary efficacy, and pharmacokinetics of the HER3 (ErbB3) mAb SAR256212 in... 
CELL LUNG-CANCER | ACTIVATION | ERBB3 | ONCOLOGY | PATHWAY | PHOSPHATIDYLINOSITOL 3-KINASE | TYROSINE KINASE | EPIDERMAL-GROWTH-FACTOR | MUTATIONS | UP-REGULATION | METASTATIC COLORECTAL-CANCER | Antibodies, Neutralizing - administration & dosage | Quinoxalines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Class I Phosphatidylinositol 3-Kinases - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Class I Phosphatidylinositol 3-Kinases - immunology | Dose-Response Relationship, Drug | Antibodies, Neutralizing - immunology | Neoplasms - genetics | Receptor, ErbB-3 - immunology | Adult | Antibodies, Neutralizing - adverse effects | Female | Quinoxalines - pharmacokinetics | Quinoxalines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Receptor, ErbB-3 - antagonists & inhibitors | Receptor, ErbB-3 - genetics | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Neoplasms - immunology | Sulfonamides - adverse effects | Aged | Mutation | Neoplasms - pathology | Sulfonamides - administration & dosage | Intravenous administration | Toxicity | Exanthema | Dosage | Metastases | Safety engineering | Toxic diseases | Safety | Drug dosages | Pharmacodynamics | Diarrhea | Pharmacology | ErbB-3 protein | Disease control | Patients | Hypotension | Constraining | 1-Phosphatidylinositol 3-kinase | Side effects | Inhibitors | Experimental design | Monoclonal antibodies | Solid tumors | Pharmacokinetics | Tumors | Cancer | Index Medicus
Journal Article
Journal Article